PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1758897
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1758897
Atherosclerosis Therapeutics
Global Atherosclerosis Therapeutics Market to Reach US$13.7 Billion by 2030
The global market for Atherosclerosis Therapeutics estimated at US$11.1 Billion in the year 2024, is expected to reach US$13.7 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2024-2030. Atherosclerosis Small Molecules, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$9.2 Billion by the end of the analysis period. Growth in the Atherosclerosis Biologics segment is estimated at 2.0% CAGR over the analysis period.
The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 6.7% CAGR
The Atherosclerosis Therapeutics market in the U.S. is estimated at US$3.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.8 Billion by the year 2030 trailing a CAGR of 6.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.
Global Atherosclerosis Therapeutics Market - Key Trends & Drivers Summarized
Why Is Atherosclerosis Still a Global Health Crisis Despite Medical Advances?
Atherosclerosis, characterized by the progressive buildup of plaque in arterial walls, remains one of the leading contributors to cardiovascular diseases worldwide. Despite decades of research and the availability of effective therapeutic interventions, it continues to claim millions of lives annually due to heart attacks, strokes, and peripheral arterial disease. This persistent prevalence is partly due to lifestyle factors such as unhealthy diets, sedentary behavior, smoking, and increasing stress levels that collectively elevate the risk of plaque formation. Furthermore, atherosclerosis often develops silently over decades before manifesting in acute cardiovascular events, which makes early detection and intervention particularly challenging. Populations in both high-income and developing countries are increasingly affected as globalization introduces western dietary habits and urbanization contributes to reduced physical activity. Compounding this issue is the rise in coexisting conditions such as diabetes, hypertension, and obesity, all of which are significant accelerators of atherosclerotic progression. Moreover, demographic shifts, especially the global increase in aging populations, have resulted in a growing patient base at risk of or already suffering from atherosclerosis-related complications. Although statins and other lipid-lowering agents have proven effective in managing cholesterol levels, they are often underutilized or insufficient for certain high-risk populations. Patient adherence, limited access to healthcare, and asymptomatic progression also hinder effective disease control. These multifaceted challenges emphasize why atherosclerosis remains an urgent global health concern and highlight the need for more sophisticated, accessible, and personalized therapeutic approaches.
How Is Innovation Reshaping the Landscape of Atherosclerosis Treatment?
The therapeutic landscape for atherosclerosis is undergoing significant transformation, fueled by advancements in biotechnology, precision medicine, and molecular research. Traditional therapies, such as statins and antiplatelet drugs, continue to form the cornerstone of treatment; however, new approaches are emerging that go beyond lipid management to address the underlying inflammatory and immune pathways driving plaque buildup. Monoclonal antibodies, such as PCSK9 inhibitors, have introduced a new era of lipid-lowering therapies that can achieve cholesterol reductions previously unattainable through conventional drugs. These biologics are particularly useful for patients with familial hypercholesterolemia or those who are statin-intolerant. Gene-editing technologies, including CRISPR, are also being explored to modify genes associated with lipid metabolism, potentially offering long-term protection against atherosclerosis. Another area of growth is RNA-based therapeutics, which can silence specific genetic targets involved in lipid synthesis or inflammation. Imaging technologies, such as intravascular ultrasound and optical coherence tomography, are now being integrated with treatment strategies to monitor plaque characteristics and assess therapeutic responses in real time. Drug-eluting stents and vascular scaffolds have evolved in both safety and efficacy, providing localized therapy that complements systemic medication. Additionally, the use of digital health tools and wearable devices is allowing for continuous cardiovascular monitoring and personalized treatment adjustments. Collectively, these innovations are not only improving outcomes for high-risk patients but also redefining how atherosclerosis is diagnosed, monitored, and managed across its entire clinical continuum.
What External Forces Are Steering the Direction of Therapeutic Development?
Beyond the scientific advancements, external factors such as healthcare policy, regulatory frameworks, economic disparities, and public awareness campaigns are playing pivotal roles in shaping the atherosclerosis therapeutics market. Government-led initiatives aimed at reducing the global burden of cardiovascular disease are resulting in broader screening programs and funding for preventive therapies, particularly in regions experiencing rapid urbanization and lifestyle shifts. Regulatory bodies are beginning to fast-track approvals for breakthrough therapies addressing high-risk atherosclerosis patients who fail to respond to standard treatments. At the same time, pharmaceutical companies are investing more aggressively in developing novel compounds, driven by the high market potential and unmet clinical needs. Health systems are increasingly favoring value-based care models, which incentivize early intervention and long-term disease management over episodic treatment. These models promote the adoption of therapeutics that not only lower cholesterol but also demonstrate reductions in cardiovascular events and mortality. Furthermore, socioeconomic disparities continue to influence treatment accessibility, with many low- and middle-income populations struggling to afford advanced therapies or maintain consistent follow-up care. This has led to increased interest in developing cost-effective generic formulations and long-acting drugs that reduce the burden of daily medication adherence. Public education and awareness campaigns are also improving patient understanding of atherosclerosis and encouraging earlier consultations, thereby supporting demand for diagnostic and therapeutic solutions. The interplay of these regulatory, economic, and societal factors is instrumental in directing the pace and focus of innovation within the atherosclerosis therapeutics sector.
What Factors Are Driving Growth in the Atherosclerosis Therapeutics Market?
The growth in the atherosclerosis therapeutics market is driven by several factors rooted in demographic trends, scientific advancement, and evolving healthcare delivery models. One of the most significant drivers is the aging global population, which presents a higher prevalence of cardiovascular risk factors, thereby increasing the demand for long-term atherosclerosis management. Simultaneously, the rising incidence of lifestyle-related conditions such as obesity, type 2 diabetes, and metabolic syndrome is expanding the pool of patients requiring treatment for atherosclerosis or its associated complications. Advances in pharmacogenomics and precision medicine are enabling more targeted therapeutic interventions, boosting efficacy and reducing adverse effects. In addition, healthcare providers are increasingly integrating digital tools that support remote monitoring and treatment adherence, thus expanding the market for supportive therapeutics that complement traditional medications. The entry of novel drug classes, including PCSK9 inhibitors, CETP inhibitors, and anti-inflammatory agents, is further enhancing therapeutic options, especially for patients resistant to first-line treatments. Payers and insurers are beginning to recognize the cost-effectiveness of early and aggressive treatment in reducing long-term healthcare expenditures, leading to more favorable reimbursement policies for advanced therapies. Furthermore, ongoing clinical trials and regulatory approvals are introducing new pipeline candidates into the market at a steady pace, keeping innovation momentum high. The shift toward holistic cardiovascular care, encompassing lifestyle management, diagnostics, and pharmaceutical intervention, is reinforcing the demand for multi-modal therapeutic approaches. As a result, the market for atherosclerosis therapeutics is not only expanding in volume but also diversifying in scope, driven by a combination of clinical need, technological evolution, and strategic healthcare planning.
SCOPE OF STUDY:
The report analyzes the Atherosclerosis Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Product (Atherosclerosis Small Molecules, Atherosclerosis Biologics)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 43 Featured) -
- Amgen Inc.
- AstraZeneca plc
- Bayer AG
- Bristol-Myers Squibb
- Daiichi Sankyo Co., Ltd.
- Eli Lilly and Company
- GlaxoSmithKline plc (GSK)
- Ionis Pharmaceuticals, Inc.
- Kowa Company, Ltd.
- Merck & Co., Inc.
- Mitsubishi Tanabe Pharma
- Novartis AG
- Novo Nordisk A/S
- Pfizer Inc.
- Regeneron Pharmaceuticals
- Roche Holding AG
- Sanofi S.A.
- Takeda Pharmaceutical Co.
- Teijin Pharma Limited
- Zai Lab Limited
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Tariff Impact on Global Supply Chain Patterns
- Atherosclerosis Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Rising Global Incidence of Cardiovascular Diseases Spurs Demand for Atherosclerosis Therapeutics
- Increased Focus on Preventive Cardiology Drives Development of Early-stage Treatment Options
- Boom in Aging Populations and Lifestyle-related Risk Factors Expands the Addressable Market
- Growing Emphasis on Personalized Medicine Throws the Spotlight on Targeted Atherosclerosis Therapies
- Advances in Lipid-lowering Agents and Anti-inflammatory Drugs Propel Pipeline Innovation
- Demand for Combination Therapies and Multimodal Treatment Strategies Strengthens Clinical Adoption
- Here's How Biomarker-driven Approaches Enhance Precision and Treatment Efficacy
- Wider Integration of AI in Drug Discovery and Trial Design Generates Acceleration in R&D
- Rising Investment in RNA-based and Gene-editing Platforms Sustains Innovation in Next-gen Therapeutics
- Expansion of Cardiometabolic Care Models Unlocks New Opportunities for Holistic Treatment Protocols
- Growing Use of Imaging and Diagnostic Tools Fuels Early Detection and Therapeutic Monitoring
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Atherosclerosis Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 3: World Historic Review for Atherosclerosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 4: World 16-Year Perspective for Atherosclerosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Atherosclerosis Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 6: World Historic Review for Atherosclerosis Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 7: World 16-Year Perspective for Atherosclerosis Small Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Atherosclerosis Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 9: World Historic Review for Atherosclerosis Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 10: World 16-Year Perspective for Atherosclerosis Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
- TABLE 11: USA Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 12: USA Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 13: USA 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- CANADA
- TABLE 14: Canada Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 15: Canada Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 16: Canada 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- JAPAN
- Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
- TABLE 17: Japan Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 18: Japan Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 19: Japan 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- CHINA
- Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
- TABLE 20: China Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 21: China Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 22: China 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- EUROPE
- Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
- TABLE 23: Europe Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 24: Europe Historic Review for Atherosclerosis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 25: Europe 16-Year Perspective for Atherosclerosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
- TABLE 26: Europe Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 27: Europe Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 28: Europe 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- FRANCE
- Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
- TABLE 29: France Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 30: France Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 31: France 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- GERMANY
- Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
- TABLE 32: Germany Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 33: Germany Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 34: Germany 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- ITALY
- TABLE 35: Italy Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 36: Italy Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 37: Italy 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- UNITED KINGDOM
- Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
- TABLE 38: UK Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 39: UK Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 40: UK 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- SPAIN
- TABLE 41: Spain Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 42: Spain Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 43: Spain 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- RUSSIA
- TABLE 44: Russia Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 45: Russia Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 46: Russia 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- REST OF EUROPE
- TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 48: Rest of Europe Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 49: Rest of Europe 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- ASIA-PACIFIC
- Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
- TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 51: Asia-Pacific Historic Review for Atherosclerosis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 52: Asia-Pacific 16-Year Perspective for Atherosclerosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
- TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 54: Asia-Pacific Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 55: Asia-Pacific 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- AUSTRALIA
- Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
- TABLE 56: Australia Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 57: Australia Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 58: Australia 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- INDIA
- Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
- TABLE 59: India Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 60: India Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 61: India 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- SOUTH KOREA
- TABLE 62: South Korea Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 63: South Korea Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 64: South Korea 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- REST OF ASIA-PACIFIC
- TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 66: Rest of Asia-Pacific Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 67: Rest of Asia-Pacific 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- LATIN AMERICA
- Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
- TABLE 68: Latin America Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 69: Latin America Historic Review for Atherosclerosis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 70: Latin America 16-Year Perspective for Atherosclerosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
- TABLE 71: Latin America Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 72: Latin America Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 73: Latin America 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- ARGENTINA
- TABLE 74: Argentina Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 75: Argentina Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 76: Argentina 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- BRAZIL
- TABLE 77: Brazil Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 78: Brazil Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 79: Brazil 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- MEXICO
- TABLE 80: Mexico Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 81: Mexico Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 82: Mexico 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- REST OF LATIN AMERICA
- TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 84: Rest of Latin America Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 85: Rest of Latin America 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- MIDDLE EAST
- Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
- TABLE 86: Middle East Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
- TABLE 87: Middle East Historic Review for Atherosclerosis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 88: Middle East 16-Year Perspective for Atherosclerosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
- TABLE 89: Middle East Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 90: Middle East Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 91: Middle East 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- IRAN
- TABLE 92: Iran Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 93: Iran Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 94: Iran 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- ISRAEL
- TABLE 95: Israel Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 96: Israel Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 97: Israel 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- SAUDI ARABIA
- TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 99: Saudi Arabia Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 100: Saudi Arabia 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- UNITED ARAB EMIRATES
- TABLE 101: UAE Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 102: UAE Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 103: UAE 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- REST OF MIDDLE EAST
- TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 105: Rest of Middle East Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 106: Rest of Middle East 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
- AFRICA
- Atherosclerosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
- TABLE 107: Africa Recent Past, Current & Future Analysis for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
- TABLE 108: Africa Historic Review for Atherosclerosis Therapeutics by Product - Atherosclerosis Small Molecules and Atherosclerosis Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
- TABLE 109: Africa 16-Year Perspective for Atherosclerosis Therapeutics by Product - Percentage Breakdown of Value Sales for Atherosclerosis Small Molecules and Atherosclerosis Biologics for the Years 2014, 2025 & 2030
IV. COMPETITION
